When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

The global weight loss and obesity management market is set to experience remarkable expansion in the coming decade. With new ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Gubra’s once-weekly obesity candidate was tied to 3% weight loss during ... a burgeoning landscape that includes Novo Nordisk ...

In recent years, interest in these medications—initially developed to treat type 2 diabetes—has exploded, primarily because ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...